SCHEMBL23522701

SCHEMBL23522701

CCN(CCO)C(=O)CC(NC(=O)O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ TRPV1 Q8NER1 7/20 0.42
▸ CTSA P10619 2/20 0.41
▸ ATM Q13315 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ GPR139 Q6DWJ6 1/20 0.41
▸ MC4R P32245 1/20 0.40
▸ TACR1 P25103 2/20 0.39
▸ KCNK3 O14649 1/20 0.39
▸ MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19301144 0.88 FAAH (0.41) L3MBTL1TRPV1CTSAGAAMEN1
SCHEMBL19300952 0.83 L3MBTL1 (0.46) L3MBTL1TRPV1MEN1ALDH1A1CYP1A2
SCHEMBL19301092 0.82 L3MBTL1 (0.45) L3MBTL1TRPV1MEN1ALDH1A1CYP1A2
SCHEMBL20743185 0.79 GAA (0.45) L3MBTL1CTSAATMGAAMEN1
SCHEMBL19301143 0.79 FAAH (0.41) L3MBTL1CTSAATMGAAMEN1
SCHEMBL23522702 0.78 L3MBTL1 (0.41) L3MBTL1CTSAMEN1ALDH1A1POLB
SCHEMBL19283643 0.78 ITGA5 (0.43) L3MBTL1TRPV1SMN1; SMN2KCNH2
SCHEMBL3447133 0.78 MAPT (0.46) L3MBTL1CTSAATMMEN1ALDH1A1
SCHEMBL3596702 0.78 KCNQ3 (0.54) L3MBTL1CTSAATMMEN1ALDH1A1
SCHEMBL3447481 0.78 KCNQ3 (0.54) L3MBTL1CTSAATMMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US disclosed
CN-109153667-B Novel potassium channel inhibitors 阿塞西翁制药公司 2021-04-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNJ2, KCNN2, KCNN1 L3MBTL1 1670/4885TRPV1 136/4885CTSA 2583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback